Contact Us
Contact Us

News & Events

Featured News

RDP Pharma AG and Experimental Drug Development Centre Launch Strategic Collaboration to Discover and Develop Monovalent Targeted Protein Degraders for Autoimmune Diseases

Recent News

Collaboration with Sprint Bioscience in Inflammatory Diseases

Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

RDP Pharma AG and Experimental Drug Development Centre Launch Strategic Collaboration to Discover and Develop Monovalent Targeted Protein Degraders for Autoimmune Diseases

Collaboration with Sprint Bioscience in Inflammatory Diseases

Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer

EBC-129: Phase 1 study of our first-in-class, anti N-glycosylated CEACAM5 & 6 ADC in solid tumours

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

First Made-in-Singapore Antibody-Drug Conjugate EBC-129 progresses to Phase 1B Dose Expansion

ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics

Helpful Links

Contact Us

© Experimental Drug Development Centre All Rights Reserved